FINWIRES · TerminalLIVE
FINWIRES

Boston Scientific Has Underappreciated Growth Drivers, UBS Says

By

Boston Scientific (BSX) has underappreciated growth drivers beyond its electrophysiology and Watchman franchises that should support continued high-single-digit organic growth, UBS said in a note Tuesday.

The firm pointed to coronary intravascular lithotripsy and renal denervation products expected in 2027 and 2028, representing a combined $2.5 billion served market, along with Empower leadless pacemaker launch in 2027 that could help the company gain share in a structurally higher-growth cardiac rhythm management market.

UBS said management's lowered growth outlook for electrophysiology and Watchman is already reflected in Street models, giving the company room to shift focus toward other high-growth areas.

The firm added that current share pricing implies sales declines through 2029, versus its own and consensus estimates for high-single-digit growth, suggesting the recent pullback is overdone.

UBS assumed coverage of Boston Scientific with a buy rating and $74 price target.

Price: $46.48, Change: $+0.97, Percent Change: +2.12%

Related Articles

Wire

AuMEGA Metals Starts Inaugural Diamond Drilling at Canada Targets; Shares Fall 9%

AuMEGA Metals (ASX:AAM) started inaugural diamond drilling at targets at Isle aux Morts Granite and and the adjoining Cape Ray West area along the Cape Ray shear zone in Canada, according to a Tuesday Australian bourse filing.The drilling program is designed to test a series of structural, geochemical, and geophysical targets defined by integrating geological mapping, surface geochemistry, geophysics, and structural interpretation, per the filing.The company's shares fell nearly 9% in recent trading on Tuesday.

ASX:AAM
Wire

Brown & Brown Q2 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q2 adjusted earnings late Monday of $1.07 per diluted share, up from $1.03 a year earlier.Analysts polled by FactSet expected $1.08.Revenue in the three months ended June 30 rose to $1.68 billion from $1.29 billion a year earlier.Analysts expected $1.71 billion.The company's shares fell 1.8% in after-hours trading.

$BRO
Wire

Celestica Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Celestica (CLS) reported Q2 adjusted earnings late Monday of $2.54 per diluted share, up from $1.39 a year earlier.Analysts polled by FactSet expected $2.27.Revenue in the three months ended June 30 rose to $4.7 billion from $2.89 billion a year earlier.Analysts expected $4.33 billion.Celestica expects Q3 adjusted EPS of $2.88 to $3.08 on revenue of $5.25 to $5.55 billion.Analysts project EPS of $2.65 on revenue of $4.94 billion.The company boosted full-year guidance to adjusted EPS of $11.30 on revenue of $20.5 billion from the prior forecast of EPS of $10.15 on revenue of $19 billion.Analysts project EPS of $10.13 on revenue of $18.95 billion.Celestica shares rose 9.4% in after-hours trading.

$CLS